Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5074037
Max Phase: Preclinical
Molecular Formula: C63H88F2N10O10
Molecular Weight: 1183.45
Molecule Type: Unknown
Associated Items:
ID: ALA5074037
Max Phase: Preclinical
Molecular Formula: C63H88F2N10O10
Molecular Weight: 1183.45
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)c1nnc(CCNC(=O)COCC(=O)NCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)n1C1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Standard InChI: InChI=1S/C63H88F2N10O10/c1-39(2)59-72-71-51(75(59)46-32-44-14-15-45(33-46)74(44)29-21-47(41-9-5-3-6-10-41)70-60(81)42-17-22-61(64,65)23-18-42)20-28-68-54(79)37-83-35-52(77)66-26-7-4-8-27-67-53(78)36-84-38-55(80)69-48-19-24-63(82)50-31-43-13-16-49(76)57-56(43)62(63,58(48)85-57)25-30-73(50)34-40-11-12-40/h3,5-6,9-10,13,16,39-40,42,44-48,50,58,76,82H,4,7-8,11-12,14-15,17-38H2,1-2H3,(H,66,77)(H,67,78)(H,68,79)(H,69,80)(H,70,81)/t44-,45+,46?,47-,48+,50+,58-,62-,63+/m0/s1
Standard InChI Key: VCSVWIWFUOSSGV-KJOWIKPPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1183.45 | Molecular Weight (Monoisotopic): 1182.6653 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Huang B, Wang H, Zheng Y, Li M, Kang G, Barreto-de-Souza V, Nassehi N, Knapp PE, Selley DE, Hauser KF, Zhang Y.. (2021) Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity., 64 (11.0): [PMID:34027668] [10.1021/acs.jmedchem.1c00408] |
Source(1):